AbCellera Biologics Inc.
ABCL · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $9 | $17 | $4 | $5 |
| % Growth | -47.6% | 303.4% | -16.1% | – |
| Cost of Goods Sold | $0 | $7 | $0 | $0 |
| Gross Profit | $9 | $10 | $4 | $5 |
| % Margin | 100% | 58.7% | 100% | 100% |
| R&D Expenses | $55 | $39 | $42 | $46 |
| G&A Expenses | $22 | $19 | $16 | $16 |
| SG&A Expenses | $25 | $22 | $19 | $19 |
| Sales & Mktg Exp. | $3 | $3 | $3 | $3 |
| Other Operating Expenses | $5 | -$2 | $5 | $13 |
| Operating Expenses | $85 | $60 | $67 | $78 |
| Operating Income | -$76 | -$50 | -$63 | -$73 |
| % Margin | -851.8% | -290.2% | -1,479.6% | -1,440.7% |
| Other Income/Exp. Net | $31 | $13 | $10 | $26 |
| Pre-Tax Income | -$45 | -$36 | -$53 | -$47 |
| Tax Expense | $12 | -$2 | -$7 | -$13 |
| Net Income | -$57 | -$35 | -$46 | -$34 |
| % Margin | -637.8% | -203.3% | -1,077.2% | -677.4% |
| EPS | -0.19 | -0.12 | -0.15 | -0.12 |
| % Growth | -58.3% | 20% | -25% | – |
| EPS Diluted | -0.19 | -0.12 | -0.15 | -0.12 |
| Weighted Avg Shares Out | 299 | 299 | 298 | 295 |
| Weighted Avg Shares Out Dil | 299 | 299 | 298 | 295 |
| Supplemental Information | – | – | – | – |
| Interest Income | $7 | $8 | $8 | $9 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $5 | $7 | $7 | $14 |
| EBITDA | -$40 | -$39 | -$52 | -$55 |
| % Margin | -449.2% | -227.3% | -1,225.5% | -1,095.3% |